Literature DB >> 19172113

Aggregation of expanded huntingtin in the brains of patients with Huntington disease.

Guylaine Hoffner1, Sylvie Souès, Philippe Djian.   

Abstract

Huntingtin containing an expanded polyglutamine causes neuronal death and Huntington disease. Although expanded huntingtin is found in virtually every cell type, its toxicity is limited to neurons of certain areas of the brain, such as cortex and caudate/putamen. In affected areas of the brain, expanded huntingtin is not found in its intact monomeric form. It is found instead in the form of N-terminal fragments, oligomers and polymers, all of which accumulate in the cortex. Whereas the oligomer is mostly soluble, the polymers and the fragments associate with each other and with other proteins to form the insoluble inclusions characteristic of the disease. It is likely that the aggregates containing expanded huntingtin are toxic to neurons, but it remains to be determined whether the oligomer or the inclusion is the toxic species.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 19172113      PMCID: PMC2633704          DOI: 10.4161/pri.1.1.4056

Source DB:  PubMed          Journal:  Prion        ISSN: 1933-6896            Impact factor:   3.931


  40 in total

1.  Huntington's disease intranuclear inclusions contain truncated, ubiquitinated huntingtin protein.

Authors:  K A Sieradzan; A O Mechan; L Jones; E E Wanker; N Nukina; D M Mann
Journal:  Exp Neurol       Date:  1999-03       Impact factor: 5.330

2.  Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology.

Authors:  C A Gutekunst; S H Li; H Yi; J S Mulroy; S Kuemmerle; R Jones; D Rye; R J Ferrante; S M Hersch; X J Li
Journal:  J Neurosci       Date:  1999-04-01       Impact factor: 6.167

3.  Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates.

Authors:  D Martindale; A Hackam; A Wieczorek; L Ellerby; C Wellington; K McCutcheon; R Singaraja; P Kazemi-Esfarjani; R Devon; S U Kim; D E Bredesen; F Tufaro; M R Hayden
Journal:  Nat Genet       Date:  1998-02       Impact factor: 38.330

4.  Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain.

Authors:  M DiFiglia; E Sapp; K O Chase; S W Davies; G P Bates; J P Vonsattel; N Aronin
Journal:  Science       Date:  1997-09-26       Impact factor: 47.728

Review 5.  Huntington's disease: seeing the pathogenic process through a genetic lens.

Authors:  James F Gusella; Marcy E MacDonald
Journal:  Trends Biochem Sci       Date:  2006-07-10       Impact factor: 13.807

6.  Differential expression of multiple transglutaminases in human brain. Increased expression and cross-linking by transglutaminases 1 and 2 in Alzheimer's disease.

Authors:  S Y Kim; P Grant; J H Lee; H C Pant; P M Steinert
Journal:  J Biol Chem       Date:  1999-10-22       Impact factor: 5.157

7.  Tissue transglutaminase contributes to disease progression in the R6/2 Huntington's disease mouse model via aggregate-independent mechanisms.

Authors:  Craig D C Bailey; Gail V W Johnson
Journal:  J Neurochem       Date:  2005-01       Impact factor: 5.372

8.  Soluble androgen receptor oligomers underlie pathology in a mouse model of spinobulbar muscular atrophy.

Authors:  Mei Li; Erica S Chevalier-Larsen; Diane E Merry; Marc I Diamond
Journal:  J Biol Chem       Date:  2006-11-22       Impact factor: 5.157

9.  A cellular model that recapitulates major pathogenic steps of Huntington's disease.

Authors:  A Lunkes; J L Mandel
Journal:  Hum Mol Genet       Date:  1998-09       Impact factor: 6.150

10.  Transglutaminase action imitates Huntington's disease: selective polymerization of Huntingtin containing expanded polyglutamine.

Authors:  P Kahlem; H Green; P Djian
Journal:  Mol Cell       Date:  1998-03       Impact factor: 17.970

View more
  11 in total

1.  Caspase-6 activity in a BACHD mouse modulates steady-state levels of mutant huntingtin protein but is not necessary for production of a 586 amino acid proteolytic fragment.

Authors:  Juliette Gafni; Theodora Papanikolaou; Francesco Degiacomo; Jennifer Holcomb; Sylvia Chen; Liliana Menalled; Andrea Kudwa; Jon Fitzpatrick; Sam Miller; Sylvie Ramboz; Pasi I Tuunanen; Kimmo K Lehtimäki; X William Yang; Larry Park; Seung Kwak; David Howland; Hyunsun Park; Lisa M Ellerby
Journal:  J Neurosci       Date:  2012-05-30       Impact factor: 6.167

2.  Contrasting effects of nanoparticle-protein attraction on amyloid aggregation.

Authors:  Slaven Radic; Thomas P Davis; Pu Chun Ke; Feng Ding
Journal:  RSC Adv       Date:  2015-12-01       Impact factor: 3.361

3.  NanoEHS beyond Toxicity - Focusing on Biocorona.

Authors:  Sijie Lin; Monika Mortimer; Ran Chen; Aleksandr Kakinen; Jim E Riviere; Thomas P Davis; Feng Ding; Pu Chun Ke
Journal:  Environ Sci Nano       Date:  2017-06-01

4.  Complete suppression of Htt fibrilization and disaggregation of Htt fibrils by a trimeric chaperone complex.

Authors:  Annika Scior; Alexander Buntru; Kristin Arnsburg; Anne Ast; Manuel Iburg; Katrin Juenemann; Maria Lucia Pigazzini; Barbara Mlody; Dmytro Puchkov; Josef Priller; Erich E Wanker; Alessandro Prigione; Janine Kirstein
Journal:  EMBO J       Date:  2017-12-06       Impact factor: 11.598

Review 5.  Therapeutic Genome Editing and In Vivo Delivery.

Authors:  Amanda Catalina Ramirez-Phillips; Dexi Liu
Journal:  AAPS J       Date:  2021-06-02       Impact factor: 4.009

6.  Huntington's Disease: An Immune Perspective.

Authors:  Annapurna Nayak; Rafia Ansar; Sunil K Verma; Domenico Marco Bonifati; Uday Kishore
Journal:  Neurol Res Int       Date:  2011-08-24

7.  Transgenic minipig model of Huntington's disease exhibiting gradually progressing neurodegeneration.

Authors:  Taras Ardan; Monika Baxa; Božena Levinská; Miroslava Sedláčková; The Duong Nguyen; Jiří Klíma; Štefan Juhás; Jana Juhásová; Petra Šmatlíková; Petra Vochozková; Jan Motlík; Zdenka Ellederová
Journal:  Dis Model Mech       Date:  2019-12-12       Impact factor: 5.758

Review 8.  Single-chain fragment variable passive immunotherapies for neurodegenerative diseases.

Authors:  Liang Huang; Xiaomin Su; Howard J Federoff
Journal:  Int J Mol Sci       Date:  2013-09-17       Impact factor: 5.923

9.  A selective inhibitor of histone deacetylase 3 prevents cognitive deficits and suppresses striatal CAG repeat expansions in Huntington's disease mice.

Authors:  Nuria Suelves; Lucy Kirkham-McCarthy; Robert S Lahue; Silvia Ginés
Journal:  Sci Rep       Date:  2017-07-20       Impact factor: 4.379

10.  Modulation of dopamine D1 receptors via histamine H3 receptors is a novel therapeutic target for Huntington's disease.

Authors:  David Moreno-Delgado; Mar Puigdellívol; Silvia Ginés; Peter J McCormick; Estefanía Moreno; Mar Rodríguez-Ruiz; Joaquín Botta; Paola Gasperini; Anna Chiarlone; Lesley A Howell; Marco Scarselli; Vicent Casadó; Antoni Cortés; Sergi Ferré; Manuel Guzmán; Carmen Lluís; Jordi Alberch; Enric I Canela
Journal:  Elife       Date:  2020-06-09       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.